KOSDAQBiotech & Pharma195990

Abpro Bio

₩846▼ 0.24%2026-11-18 close
Market Cap
₩13.8B
Turnover
₩7,234,191
Volume
8.6K
Shares out.
16.3M
PER
—
PBR
0.3×
EPS
-₩491
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

RootK: Revenue Rising, Losses Persist

RootK's quarterly revenue has risen for three straight quarters through the third quarter of 2026, but operating and net losses continue, leaving listing requirements and funding as the key items to watch.

  1. 1

    Revenue reached KRW 31.9 billion in 2025, extending a run of increases that began in 2023 and making 2025 the largest year of 2022 to 2025.

  2. 2

    The net loss attributable to controlling shareholders widened to KRW 48.9 billion in 2025, and the company has been loss-making for four consecutive years from 2022 to 2025.

  3. 3

    Net income attributable to controlling shareholders turned positive at KRW 2.07 billion in the first quarter of 2026, but the company returned to net losses of KRW 5.85 billion in the second quarter and KRW 3.15 billion in the third.

  4. 4

    A October 20, 2026 disclosure said market capitalization had stayed below KRW 20 billion for 25 consecutive trading days, raising the risk of an administrative issue designation.

  5. 5

    Shareholders approved a name change to RootK at the June 2026 meeting and added business purposes including music, video production, logistics and advertising, signaling an ongoing restructuring.

02

Business structure

RootK began as a machine tool maker. The company, then listed as Yoojinteu, made small machining centers when it listed on KOSDAQ in 2015. In August 2019 it brought in executives from U.S. antibody drug developer Abpro Corporation and changed its name to Abpro Bio.

It also acquired the intellectual property and development and commercialization rights to ABP-100 (a HER2×CD3 bispecific antibody) and ABP-201 (a VEGF×ANG-2 bispecific antibody) in the same year. Bispecific drug development has since become one pillar of the business.

In 2023 the company added subsidiary ANH, which develops module processes used in display and semiconductor equipment and secondary battery manufacturing. The business therefore spans machine tools, bio drug development and an equipment subsidiary.

Weakness in both the machinery and bio units was reported as a combined drag on 2025 results. In the bio segment, the company competes alongside listed peers such as Celltrion and Alteogen and overseas antibody developers.

Kim Yong-woon became CEO after the March 2026 shareholder meeting, and in June 2026 the company added twelve business purposes including music, events, video production, advertising and logistics. Segment revenue shares are not yet presented here because no disclosed figures for them are cited.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩7.9B-₩1.7B−21.6%
2025Q4₩6.1B-₩1.8B−29.6%
2026Q1₩7.9B-₩2.3B−28.7%
2026Q2₩9B-₩4.1B−45.6%
2026Q3₩10.3B-₩1.8B−17.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩22.1B-₩8.6B-₩8.1B−38.9%−5.8%11.7%
2023₩25.4B-₩8.8B-₩25.7B−34.7%−21.0%16.2%
2024₩31.7B-₩10.2B-₩15.6B−32.2%−14.5%30.8%
2025₩31.9B-₩9.3B-₩48.9B−29.1%−90.5%38.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue rose from KRW 22.1 billion in 2022 to KRW 25.4 billion in 2023 (up 14.8% year on year), KRW 31.7 billion in 2024 (up 24.8%) and KRW 31.9 billion in 2025 (up 0.8%). Growth was strongest in 2024 and nearly flat in 2025.

Operating losses were KRW 8.6 billion in 2022, KRW 8.81 billion in 2023, KRW 10.2 billion in 2024 and KRW 9.28 billion in 2025, a loss in each of the four years from 2022 to 2025.

The operating margin improved each year, from -38.9% in 2022 to -29.1% in 2025, but revenue growth has not yet closed the gap in fixed costs.

Net loss attributable to controlling shareholders was KRW 8.14 billion in 2022, KRW 25.7 billion in 2023 (wider), KRW 15.6 billion in 2024 (narrower) and KRW 48.9 billion in 2025 (wider again).

The 2025 net loss was far larger than the operating loss, which points to non-operating items; the detail should be checked in the annual report. Net loss including non-controlling interests matched these figures.

Operating cash flow was negative in every year, at KRW -12.5 billion in 2022, KRW -4.86 billion in 2023, KRW -5.75 billion in 2024 and KRW -6.69 billion in 2025.

On a quarterly basis, revenue bottomed at KRW 6.06 billion in the fourth quarter of 2025 (down 23.0% from the prior quarter) and then rose to KRW 7.89 billion, KRW 9.02 billion and KRW 10.3 billion in the first three quarters of 2026, up 30.8% year on year in the third quarter.

Operating losses widened from KRW 1.7 billion in the third quarter of 2025 to KRW 4.11 billion in the second quarter of 2026 before narrowing to KRW 1.79 billion in the third quarter.

The first-quarter 2026 net income of KRW 2.07 billion came despite an operating loss of KRW 2.26 billion, which suggests non-operating items; the detail should be checked in the quarterly report. Net losses attributable to controlling shareholders over the last four quarters totaled KRW 8 billion.

05

Industry analysis

RootK's three businesses are exposed to different demand cycles, so no single industry cycle explains them. The machine tool unit depends on manufacturers' equipment spending and in 2026 looks more like a base for diversification than a growth engine.

The bio unit centers on bispecific antibody development, where listed peers such as Celltrion, Alteogen and ABL Bio differ widely in scale and clinical stage. RootK is smaller than these peers and has limited financial capacity to carry its pipeline through clinical trials on its own.

Its subsidiary ANH develops module processes for display and semiconductor equipment and secondary battery manufacturing, so it follows capital spending by equipment customers in those markets. Because the subsidiary's revenue share is not disclosed here, its contribution to group earnings cannot be sized.

Compared with listed peers in the same sector, RootK's distinguishing features are rising revenue alongside losses and a relatively low debt ratio against equity.

06

Outlook

The direction RootK has set out for 2026 is a restructuring of its business. The June 12, 2026 extraordinary shareholder meeting approved a charter change to the RootK name and the addition of business purposes including music, events, video production, advertising and logistics.

Whether this translates into earnings will become clear only when the 2026 annual report shows the scale of the new businesses. On the capital side, trading was suspended in July 2026 in connection with a share consolidation, with resumption scheduled for July 30.

On August 28, 2026 the company decided to acquire KRW 500 million (face value) of its 19th convertible bonds before maturity. Convertible bond issuance and corrections continued into the first half of 2026, which shows funding has leaned on equity-linked instruments.

The largest shareholder is RemainReturns-type holder Returns Co., Ltd. with 12.61% as of April 8, 2026, and the change of control and capital raise are part of the reorganization. In bio, the progress of the bispecific pipeline and any partnership news are the main variables.

In the near term, whether revenue growth that ran through the third quarter of 2026 continues into the fourth quarter is the key test; the fourth-quarter result will appear in the annual report rather than a separate quarterly filing.

The main items to check in that filing are whether 2026 revenue exceeds KRW 31.9 billion and whether the operating loss narrows from KRW 9.28 billion.

07

Valuation

PER
—
PBR
0.3×
ROE
-14.8%
EPS
-₩491
BPS
₩2,903
Dividend per share
₩0

The price-to-book ratio sits at a low level relative to net assets, meaning the share price trades at a substantial discount to book value. Total equity at the end of 2025 was KRW 54 billion, all attributable to controlling shareholders, against total liabilities of KRW 20.7 billion.

The discount reflects accumulated losses and four straight years of negative operating cash flow. Because net losses have accumulated over the last four quarters, the price-to-earnings ratio cannot be calculated. Dividend yield is effectively nil, so the stock offers little income.

On the trend, the operating margin improved from -38.9% in 2022 to -29.1% in 2025, while net income attributable to controlling shareholders turned positive in the first quarter of 2026 before returning to losses.

Market capitalization sits below KRW 20 billion, close to the threshold that triggers the administrative issue review. Any valuation read should weigh book value against the persistence of losses.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Three straight quarters of revenue growth

Quarterly revenue rose to KRW 7.89 billion, KRW 9.02 billion and KRW 10.3 billion across the first three quarters of 2026. Third-quarter revenue was up 30.8% year on year. The recovery from the fourth-quarter 2025 low of KRW 6.06 billion is the basis for this bullish point.

Improving operating margin trend

The operating margin improved in each year from -38.9% in 2022 to -29.1% in 2025. The third-quarter 2026 operating loss of KRW 1.79 billion was narrower than the second-quarter loss of KRW 4.11 billion, so the loss trend has moved in a narrowing direction.

Relatively low debt burden

At the end of 2025 total liabilities were KRW 20.7 billion against total equity of KRW 54 billion, a debt ratio of 38.4%. The entire equity balance is attributable to controlling shareholders. The debt ratio has risen from 11.7% in 2022, but the debt load relative to equity remains limited.

09

Bear factors

Four straight years of losses and negative cash flow

The company recorded operating losses and net losses attributable to controlling shareholders in each year from 2022 to 2025. The 2025 net loss of KRW 48.9 billion widened from KRW 15.6 billion in 2024. Operating cash flow was negative in every year, reaching KRW -6.69 billion in 2025.

Renewed quarterly operating losses

The second-quarter 2026 operating loss of KRW 4.11 billion was well above the KRW 1.7 billion recorded in the third quarter of 2025. The second-quarter net loss attributable to controlling shareholders of KRW 5.85 billion followed the first-quarter profit, which means that profit was temporary. Over the last four quarters, net losses attributable to controlling shareholders total KRW 8 billion.

Listing maintenance and funding pressure

An October 20, 2026 disclosure stated that market capitalization had remained below KRW 20 billion for 25 consecutive trading days. Trading was also suspended in July 2026 in connection with a share consolidation.

Repeated convertible bond issuance and corrections, along with a change in the largest shareholder and a rights offering, show heavy reliance on external funding.

10

Risk factors

Listing and regulatory risk

The exchange disclosed that continued market capitalization below KRW 20 billion could add an administrative issue designation. Such a designation directly affects trading and fundraising.

Liquidity also shifted after trading resumed following the share consolidation, so price and volume patterns should be read together.

Funding and dilution risk

Convertible bond issuance, corrections and an early repurchase decision came in 2026. With operating cash flow negative for four consecutive years, funding relies on equity and debt instruments. If the convertible bonds convert into shares, the stakes of existing shareholders could be diluted.

Portfolio and execution risk

In June 2026 the company added music, events, video production, advertising and logistics to its business purposes. With the machinery and bio units both weak, whether expanding into new areas will lead to earnings improvement is uncertain.

Bispecific drug timelines depend heavily on clinical stage, so the pace of pipeline progress is another variable.

11

What to watch next

  1. After December 2026 (date not fixed)

    Whether market capitalization stays below KRW 20 billion and whether an administrative issue designation follows the October 20, 2026 disclosure.

  2. After December 2026 (timing not fixed)

    Disclosures on convertible bond conversions or repurchases and any rights offering, together with changes in share count and the largest shareholder's stake.

  3. Late March 2027

    The 2026 annual report. Key checks are whether 2026 revenue exceeds KRW 31.9 billion, whether the operating loss narrows from KRW 9.28 billion, and whether operating cash flow remains negative. The report should also show the early contribution from newly added businesses.

12

Overall view

RootK's revenue rose to KRW 31.9 billion in 2025, extending increases that began in 2023 for three consecutive years, and quarterly revenue has risen for three straight quarters through the third quarter of 2026. The operating margin improved from -38.9% in 2022 to -29.1% in 2025.

However, the company has posted operating losses and net losses attributable to controlling shareholders in each year from 2022 to 2025, and the 2025 net loss widened to KRW 48.9 billion. Operating cash flow was negative in all four years.

The second-quarter 2026 operating loss of KRW 4.11 billion and net losses of KRW 8 billion over the last four quarters show the loss structure has not yet ended. An exchange disclosure on market capitalization below KRW 20 billion and reliance on external funding are weak points for listing and dilution.

On the other side, a debt ratio of 38.4% and total equity of KRW 54 billion indicate remaining financial capacity. The name change and expanded business purposes show a direction, but their earnings contribution has not yet been shown.

The next checkpoints are revenue and operating loss in the 2026 annual report and any administrative issue designation.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. valueline.co.kr
  2. meerae.ai
  3. digitaltoday.co.kr
  4. google.com
  5. valueline.co.kr
  6. markets.hankyung.com
  7. kokstock.com
  8. google.com
  9. markets.hankyung.com
  10. press9.kr
  11. news.nate.com
  12. marketscreener.com
  13. goinsider.kr
  14. panabee.com
  15. saramin.co.kr
  16. v.daum.net
  17. kr.investing.com
  18. tipranks.com

Report written 2026-11-19 · Data as of 2026-11-18

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis